Recruiting NCT07045857
Recurrence of H Pylori : Incidence and Influential Factors.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: follow up of patients that had H. Pylori infection and recieved medical treatment for recurrence.
- Who it may be relevant to
- Registry conditions: H. Pylori Infection. Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Recurrence of H Pylori : Incidence and Influential Factors in Sohag Government.
Overview
This study aims to determine recurrence rates, identify influential factors, investigate key factors that contribute to recurrence, evaluate treatment effectiveness and to assess the efficacy of different eradication regimens and their role in reducing recurrence.
Interventions
- Behavioral follow up of patients that had H. Pylori infection and recieved medical treatment for recurrence
follow up of patients that had H. Pylori infection and recieved medical treatment for recurrence and influential factors for recurrence
Primary outcome measures
- recurrence of H. Pylori infection in patients who recieved medical treatment [Time frame: 4 weeks after successful medical treatment]
Eligibility criteria
Inclusion criteria
- Age: 18-75 years old.
- H. pylori infection: Confirmed by endoscopy, biopsy, or non-invasive tests (e.g., urea breath test, stool antigen test).
- Symptoms: Presence of dyspepsia, peptic ulcer disease, or other H. pylori-related symptoms.
- Laboratory tests: Normal liver and kidney function, and no significant abnormalities in blood counts.
Exclusion criteria
- Patients receiving eradication therapy in the past taking proton pump inhibitors,, H2 blockers ,,bismuth ,, antibiotics or other medications that interfere with the result of the examination in the recent 4 weeks.
- Gastrointestinal disorders: Severe gastrointestinal disorders (e.g., gastric cancer, inflammatory bowel disease ,gastric or duodenal ulcer with current or recent bleeding , or clinical significant gastrointestinal bleeding within 4 weeks of randomization).
- Malignancies: Active or recent malignancies.
- Severe comorbidities: Unstable or severe comorbidities (e.g., heart failure, liver cirrhosis).
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Screening
Study locations
Egypt · 1 center
- Sohag University Hospital — Sohag
Publications
- Mitchell HM, Hu P, Chi Y, Chen MH, Li YY, Hazell SL. A low rate of reinfection following effective therapy against Helicobacter pylori in a developing nation (China). Gastroenterology. 1998 Feb;114(2):256-61. doi: 10.1016/s0016-5085(98)70475-5. PMID 9453484
- Chen TS, Tsay SH, Chang FY, Lee SD. Triple therapy for the eradication of Helicobacter pylori and reduction of duodenal ulcer relapse: comparison of 1 week and 2 week regimens and recrudescence rates over 12 months. J Gastroenterol Hepatol. 1995 May-Jun;10(3):300-5. doi: 10.1111/j.1440-1746.1995.tb01097.x. PMID 7548807
- Anand PS, Kamath KP, Anil S. Role of dental plaque, saliva and periodontal disease in Helicobacter pylori infection. World J Gastroenterol. 2014 May 21;20(19):5639-53. doi: 10.3748/wjg.v20.i19.5639. PMID 24914323
Identifiers
NCT: NCT07045857 · Soh-Med--25-5-11MS